BAX · Q2 2026 Earnings

Bullish

Baxter International

Reported July 30, 2026

30-second summary

Baxter delivered $2.96B in Q2 revenue (+5% YoY, +5% organic) and adjusted EPS of $0.56 vs. $0.37 consensus — a 51% beat aided by a $0.11/share IEEPA tariff refund — and raised FY2026 adjusted EPS guide to $1.95–$2.15 from $1.85–$2.05, organic sales growth to 2–3% from ~flat, and reported growth to 3–4% from flat-to-1%. Adjusted operating margin held at 14.2% with the FY 13–14% range reaffirmed, meaning management took the top-line up without conceding margin. Two quarters ago this was a bearish reset; this quarter is the first real evidence the H2-weighted thesis is landing early.

Headline numbers

EPS

Q2 FY2026

$0.56

Revenue

Q2 FY2026

$2.96B

+5.0% YoY

+5.7% vs est.

Gross margin

Q2 FY2026

34.9%

Free cash flow

Q2 FY2026

$0.18B

Operating margin

Q2 FY2026

7.3%

Key financials

Q2 FY2026

Metric	Q2 FY2026	Q2 FY2025	YoY	Q1 FY2026	QoQ
Revenue	$2.96B	$2.81B	+5.3%	$2.70B	+9.6%
EPS	$0.56	$0.59	-5.1%	$0.36	+55.6%
Gross margin	34.9%	35.3%	-40bps	33.0%	+190bps
Operating margin	7.3%	6.8%	+50bps	2.4%	+490bps
Free cash flow	$0.18B	—	—	$0.08B	+138.2%

Guidance

Company raises full-year 2026 EPS and organic growth guidance significantly following strong Q2 beat; reported sales growth revised from flat-1% to 3-4%, organic growth from flat to 2-3%, and EPS from $1.85-$2.05 to $1.95-$2.15.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	Q2 FY2026	—	$2.96B	+5.7% vs consensus estimate of $2.80B	Beat
Adjusted EPS (continuing operations)	Q2 FY2026	—	$0.56	+51.4% vs consensus estimate of $0.37	Beat

New guidance

Metric	Period	Guide	YoY
Gross margin	Q2 FY2026	34.9%	—
Operating margin (GAAP)	Q2 FY2026	7.3%	—
Free cash flow	Q2 FY2026	$0.181B	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Adjusted EPS (continuing operations)	FY 2026	$1.85 to $2.05	$1.95 to $2.15	+$0.10 on low end, +$0.10 on high end	Raised
Reported sales growth from continuing operations	FY 2026	flat to 1%	3% to 4%	+3.0 to +4.0 pts	Raised
Organic sales growth from continuing operations	FY 2026	approximately flat	2% to 3%	+2.0 to +3.0 pts	Raised

Reaffirmed unchanged this quarter: Adjusted operating margin from continuing operations (13% to 14%)

Segment KPIs

Q2 FY2026

Segment	Q2 FY2026	Q2 FY2025	YoY
Medical Products & Therapies	$2.076B	$1.32B	+57.3%
Infusion Therapies & Platforms	$1.745B	—	+6.0%
Advanced Surgery	$0.331B	—	+12.0%
Healthcare Systems & Technologies	$0.801B	$0.767B	+4.4%
Care & Connectivity Solutions	$0.502B	—	+6.0%
Front Line Care	$0.299B	—	+2.0%
Medical Products & Therapies Organic Growth	5.0%	—	—
Healthcare Systems & Technologies Organic Growth	4.0%	—	—

Other KPIs

Q2 FY2026

Segment	Q2 FY2026	Q2 FY2025	YoY
U.S. Sales	$1.595B	$1.536B	+3.8%
International Sales	$1.365B	$1.274B	+7.1%
Adjusted Operating Income	$421M	$423 million	—
Operating Margin (GAAP)	7.3%	—	—
Adjusted Operating Margin	14.2%	—	—
Organic Sales Growth	5.0%	—	—
Free Cash Flow	$181M	—	—
IEEPA Tariff Refund Benefit	$0.11 per share	—	—

Management tone

Q3 2025 "reset and stabilize" → Q4 2025 "early-stage turnaround" → Q1 2026 "GPS execution discipline" → Q2 2026 "raise and reaffirm."

Note: no earnings call transcript was available for this quarter; tone analysis is drawn from the press release and inferred from the guidance action itself.

The guidance action itself is the tone shift. Three quarters ago management cut FY guide across every line and slashed the dividend. Two quarters ago they set a FY2026 organic-flat, EPS $1.85–$2.05 bar deliberately below what most sell-side had modeled. Last quarter they reaffirmed that bar with -1% organic in Q1. This quarter they raised the top-line guide 200–300bps and the EPS guide 5% at the midpoint after one clean quarter of outperformance. That sequence — under-promise, deliver, raise early — is the opposite of the pattern that defined the prior CEO's tenure and the first material evidence that Hider's "higher say-do ratio" is more than a slogan.

The press release language moved from defensive to confident, without overreaching. The company frames Q2 as "second-quarter results exceeded expectations on both the top and bottom lines" and cites "steady progress and core operating momentum." Notably absent: the "most challenging quarter," "prudent downside," and "early-stage turnaround" framings that dominated the last three prints. Also absent: any victory lap or long-term target upgrade. The raise is calibrated — one quarter of data, one increment of guide — which is exactly the discipline the Q4 2025 "multi-year turnaround" framing promised.

Margin discipline held despite top-line acceleration. Reaffirming 13–14% adj. operating margin while raising reported growth 300bps implies management is either sandbagging the margin line or reinvesting the operating leverage into R&D and cost actions. Either read is bullish: sandbagging preserves upside into H2; reinvestment supports the multi-year thesis. What it is not is a company chasing near-term margin optics at the expense of the turnaround plan.

Answers to last quarter's watch list

Q2 adj. operating margin step-up — Q2 adj. operating margin printed 14.2%, well above the 12.5–13.0% threshold and comfortably inside the FY 13–14% band. This is the single most important data point on the print: the H2-weighted margin thesis is no longer purely load-bearing because Q2 already sits in the target range.

Resolved positively

U.S. organic sales inflection — U.S. reported +4% in Q2 vs. -4% in Q1 and -1% operational in Q4 — a nine-point swing in a single quarter. The "structural U.S. problem" question is answered in the negative for now, though one quarter does not close the file.

Resolved positively

Novum customer-return realization — The press release does not quantify customer returns in Q2. The fact that Infusion Therapies grew +6% suggests either returns did not materialize at material scale or growth elsewhere in the sub-segment absorbed them. Without call commentary, the specific dollar impact remains undisclosed.

Continue monitoring

Re-introduction of withdrawn EPS-bridge metrics — The press release does not restate the tax rate, share count, non-operating expense, or tariff lines that were withdrawn in Q1. The FY EPS guide was raised without formally re-quantifying the components — a modest transparency negative that the guide raise partially offsets.

Not resolved

GPS event count and operational KPIs — No GPS event count or operational KPI update was disclosed in the press release. Whether Hider updated the 230+ Q1 figure on the call is unknown.

Continue monitoring

2027 framing — No 2027-specific commentary appears in the press release. Whether Q&A restated or walked back the "modest sales and earnings growth" 2027 signal from Q1 cannot be assessed.

Continue monitoring

What to watch into next quarter

Q3 organic growth against the new 2–3% FY guide — the new FY organic guide implies H2 organic of ~2–4%; a Q3 print below +2% would suggest Q2 was a one-time inflection and could force the guide back down.

Adj. operating margin sustainability — Q2 at 14.2% sits at the high end of the FY band; watch whether H2 holds above 13% or whether one-time Q2 benefits (including the IEEPA refund flowing through the P&L) inflated the run-rate.

Ex-tariff-refund EPS trajectory — Q2 adj. EPS was $0.56 including $0.11/share IEEPA benefit; clean EPS was ~$0.45. H2 needs to average ~$0.51–$0.62 clean to hit the new $1.95–$2.15 band without further one-time items.

U.S. sales durability — U.S. inflected from -4% to +4% in one quarter; watch whether Q3 sustains U.S. positive growth or gives back the recovery. A single-quarter bounce does not close the structural question.

Novum resolution milestones and customer returns — six months into the "full-year 2026" ship-and-install hold, watch for any FDA submission, corrective action timeline, or the first quantified customer-return figure. Continued silence extends the attrition window into 2027.

Ancillary FY guide transparency — watch whether Q3 disclosure re-introduces the tax rate, share count, non-operating expense, and tariff quantification withdrawn in Q1. Continued absence limits investor ability to independently bridge the EPS raise.

Sources

Baxter International Q2 2026 press release / 8-K Exhibit 99.1 — https://www.sec.gov/Archives/edgar/data/10456/000162828026050795/bax-20260630xex991.htm
Tapebrief Q1 FY2026 BAX coverage (prior watch list and FY2026 guide baseline)
Tapebrief Q4 FY2025 BAX coverage (original FY2026 guide and turnaround framing)
Tapebrief Q3 FY2025 BAX coverage (multi-quarter tone arc)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.